The 60-second version of Shree Pacetronix Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹20 Cr | ₹22 Cr | ₹17 Cr | ₹22 Cr | +2.2% |
| EBITDA | ₹6 Cr | ₹6 Cr | ₹2 Cr | ₹5 Cr | -1.8% |
| EBITDA Margin | 28.0% | 26.9% | 14.5% | 24.8% | — |
| PAT (Net Profit) | ₹3 Cr | ₹3 Cr | ₹1 Cr | ₹3 Cr | -1.2% |
| EPS | ₹9.06 | ₹9.33 | ₹2.08 | ₹8.47 | -2.2% |
| ROE | 33.7% | 25.8% | 5.4% | 17.4% | — |
| ROCE | 48.4% | 36.6% | 11.5% | 25.0% | — |
| Total Debt | ₹2 Cr | ₹4 Cr | ₹5 Cr | ₹3 Cr | +7.1% |
| Free Cash Flow | ₹0 Cr | -₹0 Cr | -₹1 Cr | ₹2 Cr | +54.4% |
| Company | P/E | ROE |
|---|---|---|
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| CIPLA LTD | 31.8x | 9.8% |
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| APOLLO HOSPITALS ENTER. L | 54.3x | 22.0% |
A reasonable business at a reasonable price. Nothing here is alarming and nothing is compelling, which usually means the decision rests on things this data cannot see — the industry's direction, management's intent, and what else is available to you. 1 high-severity red flag sits above this conclusion and should be read first.